Longitudinal prediction of progression in MS: The PrograMS Cohort

Longitudinal prediction of progression in MS: The PrograMS Cohort - PrograMS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON51918

Enrollment

300

Registered

2021-03-10

Start date

2021-05-25

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disseminated sclerosis MS

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All people with MS and all healthy controls (HC) who have previously participated in the Presto (2002/140), GeneOCT(2004/9), or LTD (2010/336) studies (collectively also known as *PrograMS*) and have not provided objection to be contacted for follow-up study, or have been enquired to join the cohort based on the Amsterdam MS Cohort (2020/269) protocol.

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: MS patients: - Persons unable to undergo the minimal data collection (as described in Methods section) Controls: - Comorbidity that interferes with participation in this study

Design outcomes

Primary

Measure	Time frame
Cognitive measures • Neuropsychological test scores. Neurological measures • Clinical scales. Blood serum measures • (Changes in) blood biomarkers as defined in the MS biobank protocol. Neuro-ophthalmological measures • (Changes in) retinal layer integrity and eye movements. Questionnaires • (Changes in) mood and anxiety, fatigue, sleep disturbances, quality of life, coping style, personality, subjective motor function and cognitive complaints, work participation, stress, resilience. Structural brain measures • (Changes in) white and grey matter tissue integrity and volume, as well as lesions. Functional brain measures • (Changes in) functional activation as well as connectivity and network changes, measured with fMRI and MEG.	—

Measure

Time frame

Cognitive measures • Neuropsychological test scores. Neurological measures • Clinical scales. Blood serum measures • (Changes in) blood biomarkers as defined in the MS biobank protocol. Neuro-ophthalmological measures • (Changes in) retinal layer integrity and eye movements. Questionnaires • (Changes in) mood and anxiety, fatigue, sleep disturbances, quality of life, coping style, personality, subjective motor function and cognitive complaints, work participation, stress, resilience. Structural brain measures • (Changes in) white and grey matter tissue integrity and volume, as well as lesions. Functional brain measures • (Changes in) functional activation as well as connectivity and network changes, measured with fMRI and MEG.

—

Secondary

Measure	Time frame
We will identify (novel, clinical) measures and combinations of measures (e.g. grey matter atrophy patterns, serum NfL levels, dynamic network changes, structural network topology) to better understand the mechanism underlying progression, as well as (combinations of) measures that are most predictive for clinical progression.	—

Countries

Netherlands

Outcome results